EMS IPO oversubscribed 15 times on Day 2 of bidding
The initial public offering (IPO) of EMS Limited, a water and wastewater collection, treatment, and disposal services provider, was subscribed 15 times on the second day of bidding on September 11.
Investors bought 16.21 crore shares, which were 15.03 times higher compared to the issue size of 1.07 crore shares.
High net-worth individuals (HNIs) and retail investors seem to be more bullish on the company as they have bid 29.71 times and 16.59 times the allotted quota which is 15 percent and 35 percent of the issue size respectively.
Qualified institutional buyers (QIBs) have bought 67 percent shares of the reserved portion which is 50 percent of the IPO size.
The Rs 321.24-crore public issue comprises a fresh issuance of shares worth Rs 146.24 crore, and an offer-for-sale (OFS) of Rs 175 crore by promoter Ranveer Singh, at the upper price band.
The price band for the offer is Rs 200-211 per share.
The company has already raised Rs 96.37 crore on September 7, a day before the issue opening, via a fully booked anchor book. Saint Capital Fund, Abakkus Diversified Alpha Fund, Morgan Stanley Asia (Singapore), and BofA Securities Europe SA – ODI among six investors participated in the anchor book.
The company will utilise fresh issue proceeds mainly for working capital requirements amounting to Rs 101.24 crore, and the remaining for general corporate purposes.
The IPO will close on September 12.
Here are some key takeaways from the article:
- The EMS IPO was oversubscribed 15 times on the second day of bidding.
- HNIs and retail investors were the most bullish on the company, bidding 29.71 times and 16.59 times the allotted quota respectively.
- QIBs have bought 67 percent shares of the reserved portion.
- The company has already raised Rs 96.37 crore via a fully booked anchor book.
- The IPO will close on September 12.
- 22 Sep
Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits
Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.
- 22 Sep
Signature Global IPO Subscribed 11.88 Times on Final Day
The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.
- 22 Sep
Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding
Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.
- 22 Sep
Pharma company Valiant Laboratories to go public on September 27
Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.
- 21 Sep
Unihealth Consultancy makes tepid debut on NSE Emerge
Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.